BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 7849309)

  • 21. Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice.
    Waurzyniak BJ; Heerema N; Sensel MG; Gaynon PS; Kraft P; Sather HN; Chelstrom L; Reaman GH; Uckun FM
    Leuk Lymphoma; 1998 Dec; 32(1-2):77-87. PubMed ID: 10037003
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human t(4;11)(q21;q23) acute lymphoblastic leukemia in mice with severe combined immunodeficiency.
    Uckun FM; Downing JR; Chelstrom LM; Gunther R; Ryan M; Simon J; Carroll AJ; Tuel-Ahlgren L; Crist WM
    Blood; 1994 Aug; 84(3):859-65. PubMed ID: 8043867
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia.
    Ito Y; Wasserman R; Galili N; Reichard BA; Shane S; Lange B; Rovera G
    J Clin Oncol; 1993 Mar; 11(3):546-53. PubMed ID: 8445430
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Childhood acute myeloid leukemia in mice with severe combined immunodeficiency.
    Chelstrom LM; Gunther R; Simon J; Raimondi SC; Krance R; Crist WM; Uckun FM
    Blood; 1994 Jul; 84(1):20-6. PubMed ID: 8018918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of variables determining the engraftment potential of human acute myeloid leukemia in the immunodeficient NOD/SCID human chimera model.
    Rombouts WJ; Martens AC; Ploemacher RE
    Leukemia; 2000 May; 14(5):889-97. PubMed ID: 10803522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute lymphoblastic leukemias from relapse engraft more rapidly in SCID mice.
    Palucka AK; Scuderi R; Porwit A; Jeha S; Gruber A; Björkholm M; Beran M; Pisa P
    Leukemia; 1996 Mar; 10(3):558-63. PubMed ID: 8642875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A human acute lymphoblastic leukemia line with the T(4;11) translocation as a model of minimal residual disease in SCID mice.
    Gobbi A; Di Berardino C; Scanziani E; Garofalo A; Rivolta A; Fontana G; Rambaldi A; Giavazzi R; Biondi A
    Leuk Res; 1997; 21(11-12):1107-14. PubMed ID: 9444945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice.
    Nijmeijer BA; Mollevanger P; van Zelderen-Bhola SL; Kluin-Nelemans HC; Willemze R; Falkenburg JH
    Exp Hematol; 2001 Mar; 29(3):322-9. PubMed ID: 11274760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Behm FG; Hancock ML; Razzouk BI; Ribeiro RC; Rivera GK; Rubnitz JE; Sandlund JT; Pui CH; Campana D
    Blood; 2002 Jul; 100(1):52-8. PubMed ID: 12070008
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective homing of human leukemic B-cell precursors to specific lymphohematopoietic microenvironments in SCID mice: a role for the beta 1 integrin family surface adhesion molecules VLA-4 and VLA-5.
    Messinger Y; Chelstrom L; Gunther R; Uckun FM
    Leuk Lymphoma; 1996 Sep; 23(1-2):61-9. PubMed ID: 9021687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
    Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
    N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia.
    Sievers EL; Lange BJ; Alonzo TA; Gerbing RB; Bernstein ID; Smith FO; Arceci RJ; Woods WG; Loken MR
    Blood; 2003 May; 101(9):3398-406. PubMed ID: 12506020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Kitanaka A; Pui CH; McNinch L; Evans WE; Raimondi SC; Behm FG; Aricò M; Campana D
    Blood; 1996 Feb; 87(3):1140-6. PubMed ID: 8562940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.
    Uckun FM; Gaynon PS; Stram DO; Sensel MG; Sarquis MB; Lazarus KH; Willoughby M
    Clin Cancer Res; 1999 Sep; 5(9):2415-20. PubMed ID: 10499612
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia.
    Thomas X; Archimbaud E; Charrin C; Magaud JP; Fiere D
    Leukemia; 1995 Feb; 9(2):249-53. PubMed ID: 7532767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling.
    Spiegel A; Kollet O; Peled A; Abel L; Nagler A; Bielorai B; Rechavi G; Vormoor J; Lapidot T
    Blood; 2004 Apr; 103(8):2900-7. PubMed ID: 15070661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry.
    Sievers EL; Lange BJ; Buckley JD; Smith FO; Wells DA; Daigneault-Creech CA; Shults KE; Bernstein ID; Loken MR
    J Natl Cancer Inst; 1996 Oct; 88(20):1483-8. PubMed ID: 8841024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia.
    Pui CH; Hancock ML; Head DR; Rivera GK; Look AT; Sandlund JT; Behm FG
    Blood; 1993 Aug; 82(3):889-94. PubMed ID: 7687897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children.
    Ng SM; Ariffin WA; Lin HP; Chan LL; Chin YM
    J Trop Pediatr; 2000 Apr; 46(2):73-8. PubMed ID: 10822932
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin.
    Gunther R; Chelstrom LM; Tuel-Ahlgren L; Simon J; Myers DE; Uckun FM
    Blood; 1995 May; 85(9):2537-45. PubMed ID: 7537120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.